Selected article for: "constitutive activation and human malignancy"

Author: Li, Lv; Dai, Hong-Juan; Ye, Mao; Wang, Shu-Ling; Xiao, Xiao-Juan; Zheng, Jie; Chen, Hui-Yong; Luo, Yu-hao; Liu, Jing
Title: Lycorine induces cell-cycle arrest in the G0/G1 phase in K562 cells via HDAC inhibition
  • Document date: 2012_11_23
  • ID: 13amcxh2_1
    Snippet: Leukemia is a type of fatal hematological malignancy. Human chronic myelocytic leukemia (CML), a common type of leukemia, is a myeloproliferative disorder characterized by increased proliferation of granulocytic cell lines with loss capacity to differentiate. CML originates from a constitutive activation of Bcr-Abl tyrosine kinase, which develops from Philadelphia chromosome translocation. Imatinib mesylate (Glivec), a selective inhibitor of Bcr-.....
    Document: Leukemia is a type of fatal hematological malignancy. Human chronic myelocytic leukemia (CML), a common type of leukemia, is a myeloproliferative disorder characterized by increased proliferation of granulocytic cell lines with loss capacity to differentiate. CML originates from a constitutive activation of Bcr-Abl tyrosine kinase, which develops from Philadelphia chromosome translocation. Imatinib mesylate (Glivec), a selective inhibitor of Bcr-Abl, was developed as the first moleculetargeted anticancer drug to treat CML patients. However, many patients report developing resistance to Glivec due to mutations in the Abl kinase domain [1, 2] . Considering the difficulties inherent in the current CML therapy, the discovery and development new treatment approaches for CML treatment remains an urgent necessity.

    Search related documents:
    Co phrase search for related documents
    • Abl kinase and Bcr Abl selective inhibitor: 1
    • Abl kinase and CML patient: 1
    • Abl kinase and CML treatment: 1
    • Abl tyrosine kinase and Bcr Abl selective inhibitor: 1
    • Abl tyrosine kinase and CML patient: 1
    • anticancer drug and cell line: 1, 2, 3, 4, 5, 6
    • anticancer drug and CML therapy: 1
    • anticancer drug and development discovery: 1, 2
    • cell line and common type: 1, 2, 3, 4
    • cell line and constitutive activation: 1, 2
    • cell line and development discovery: 1, 2, 3, 4
    • CML patient and common type: 1
    • CML therapy and common type: 1
    • CML treatment and common type: 1
    • common type and development discovery: 1